{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:07:11Z","timestamp":1792058831174,"version":"4.4.0"},"reference-count":54,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1016\/j.juro.2009.04.015","type":"journal-article","created":{"date-parts":[[2009,6,15]],"date-time":"2009-06-15T08:09:50Z","timestamp":1245053390000},"page":"499-508","source":"Crossref","is-referenced-by-count":50,"title":["Chemoprevention of Prostate Cancer"],"prefix":"10.1097","volume":"182","author":[{"given":"Ian M.","family":"Thompson","sequence":"first","affiliation":[{"name":"Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, the Fred Hutchinson Cancer Research Center, Seattle, Washington, the Department of Pathology, University of Colorado Health Science Center, Denver, Colorado, and the Glickman Urology and Kidney Institute, The Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M.","family":"Tangen","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, the Fred Hutchinson Cancer Research Center, Seattle, Washington, the Department of Pathology, University of Colorado Health Science Center, Denver, Colorado, and the Glickman Urology and Kidney Institute, The Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phyllis J.","family":"Goodman","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, the Fred Hutchinson Cancer Research Center, Seattle, Washington, the Department of Pathology, University of Colorado Health Science Center, Denver, Colorado, and the Glickman Urology and Kidney Institute, The Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Scott","family":"Lucia","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, the Fred Hutchinson Cancer Research Center, Seattle, Washington, the Department of Pathology, University of Colorado Health Science Center, Denver, Colorado, and the Glickman Urology and Kidney Institute, The Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric A.","family":"Klein","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, the Fred Hutchinson Cancer Research Center, Seattle, Washington, the Department of Pathology, University of Colorado Health Science Center, Denver, Colorado, and the Glickman Urology and Kidney Institute, The Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2009.04.015_bib1","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1001\/jama.280.18.1569","article-title":"Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey","volume":"280","author":"Eisenberg","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.juro.2009.04.015_bib2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3322\/canjclin.35.1.36","article-title":"Probabilities of eventually developing or dying of cancer\u2013United States, 1985","volume":"35","author":"Seidman","year":"1985","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.juro.2009.04.015_bib3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3322\/CA.2007.0010","article-title":"Cancer statistics 2008","volume":"58","author":"Jemal","year":"2008","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.juro.2009.04.015_bib4","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1093\/jnci\/djg040","article-title":"Annual report to the nation on the status of cancer, 1975\u20132000, featuring the uses of surveillance data for cancer prevention and control","volume":"95","author":"Weir","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.juro.2009.04.015_bib5","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.289.11.1414","article-title":"Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence?","volume":"289","author":"Sirovich","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.juro.2009.04.015_bib6","doi-asserted-by":"crossref","first-page":"251S","DOI":"10.1016\/S0197-2456(00)00097-0","article-title":"The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status","volume":"21","author":"Gohagan","year":"2000","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.juro.2009.04.015_bib7","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.urolonc.2008.03.011","article-title":"Screening for prostate cancer (PC)\u2013an update on recent findings of the European Randomized Study of Screening for Prostate Cancer (ERSPC)","volume":"26","author":"Schr\u00f6der","year":"2008","journal-title":"Urol Oncol"},{"key":"10.1016\/j.juro.2009.04.015_bib8","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1001\/jama.276.24.1957","article-title":"Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group","volume":"276","author":"Clark","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.juro.2009.04.015_bib9","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1093\/jnci\/90.16.1219","article-title":"Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer","volume":"90","author":"Yoshizawa","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.juro.2009.04.015_bib10","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1093\/jnci\/85.18.1483","article-title":"Nutrition intervention trials in Linxian, China: supplementation with specific vitamin\/mineral combinations, cancer incidence, and disease-specific mortality in the general population","volume":"85","author":"Blot","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.juro.2009.04.015_bib11","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000157115","article-title":"Current ideas on selenium as a chemopreventive agent","volume":"7","author":"Medina","year":"1988","journal-title":"Pathol Immunopath Res"},{"key":"10.1016\/j.juro.2009.04.015_bib12","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199404143301501","article-title":"The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers","volume":"330","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.juro.2009.04.015_bib13","series-title":"Antioxidant Status, Diet, Nutrition, and Health","article-title":"Vitamin E: tocopherols and tocotrienols","author":"Pappas","year":"1998"},{"key":"10.1016\/j.juro.2009.04.015_bib14","first-page":"887","article-title":"Vitamin and mineral supplement use is associated with reduced risk of prostate cancer","volume":"8","author":"Kristal","year":"1999","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.juro.2009.04.015_bib15","doi-asserted-by":"crossref","first-page":"8037","DOI":"10.1158\/1078-0432.CCR-04-1208","article-title":"Inhibition of cyclooxygenase (COX)-2 expression by Tet-inducible COX-2 antisense cDNA in hormone-refractory prostate cancer significantly slows tumor growth and improves efficacy of chemotherapeutic drugs","volume":"10","author":"Dandekar","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.juro.2009.04.015_bib16","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1200\/JCO.2005.03.7804","article-title":"Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy or radiation therapy","volume":"24","author":"Smith","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2009.04.015_bib17","doi-asserted-by":"crossref","first-page":"5895","DOI":"10.1158\/1078-0432.CCR-06-1039","article-title":"Vitamin D inhibits the formation of prostatic intraepithelial neoplasia in Nkx3.1;Pten mutant mice","volume":"12","author":"Banach-Petrosky","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.juro.2009.04.015_bib18","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1158\/1055-9965.2225.13.12","article-title":"Randomized study of high-dose pulse calcitriol or placebo prior to radical prostatectomy","volume":"13","author":"Beer","year":"2004","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.juro.2009.04.015_bib19","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/01635580701621338","article-title":"A combination of tomato and soy products for men with recurring prostate cancer and rising prostate specific antigen","volume":"60","author":"Grainger","year":"2008","journal-title":"Nutr Cancer"},{"key":"10.1016\/j.juro.2009.04.015_bib20","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/sj.pcan.4500953","article-title":"Effects of soy phytoestrogens on the prostate","volume":"10","author":"Goetzl","year":"2007","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.juro.2009.04.015_bib21","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/MOU.0b013e3282f9b3cc","article-title":"Review of recent evidence in support of a role for statins in the prevention of prostate cancer","volume":"18","author":"Hamilton","year":"2008","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.juro.2009.04.015_bib22","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1158\/1055-9965.EPI-07-0531","article-title":"Statin induces apoptosis and cell growth arrest in prostate cancer cells","volume":"17","author":"Hoque","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.juro.2009.04.015_bib23","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ucl.2007.09.006","article-title":"Inflammation and prostate cancer: a future target for prevention and therapy?","volume":"35","author":"Stock","year":"2008","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.juro.2009.04.015_bib24","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/jnci\/dji173","article-title":"A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence","volume":"97","author":"Jacobs","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.juro.2009.04.015_bib25","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.juro.2006.04.011","article-title":"Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIB clinical trial","volume":"176","author":"Price","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2009.04.015_bib26","first-page":"1370","article-title":"Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model","volume":"62","author":"Raghow","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.juro.2009.04.015_bib27","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/jama.2008.864","article-title":"Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)","volume":"301","author":"Lippman","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.juro.2009.04.015_bib28","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1046\/j.1464-410X.2003.04167.x","article-title":"Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial","volume":"91","author":"Duffield-Lillico","year":"2003","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2009.04.015_bib29","doi-asserted-by":"crossref","first-page":"1427S","DOI":"10.1093\/ajcn\/62.6.1427S","article-title":"Effects of alpha-tocopherol and beta-carotene supplements on cancer incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study","volume":"62","author":"Albanes","year":"1995","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.juro.2009.04.015_bib30","first-page":"518","article-title":"The association between lung and prostate cancer risk, and serum micronutrients: results and lessons learned from beta-carotene and retinol efficacy trial","volume":"12","author":"Goodman","year":"2003","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.juro.2009.04.015_bib31","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0022-5347(05)65759-X","article-title":"SELECT: the next prostate cancer prevention trial. Selenum and Vitamin E Cancer Prevention Trial","volume":"166","author":"Klein","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2009.04.015_bib32","doi-asserted-by":"crossref","first-page":"217","DOI":"10.7326\/0003-4819-147-4-200708210-00175","article-title":"Effects of long-term selenium supplementation on the incidence of type 2 diabetes: a randomized trial","volume":"147","author":"Stranges","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.juro.2009.04.015_bib33","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1210\/jc.75.4.1022","article-title":"Prostate visualization studies in males homozygous and heterozygous for 5 alpha-reductase deficiency","volume":"75","author":"Imperato-McGinley","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.juro.2009.04.015_bib34","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.eururo.2007.10.052","article-title":"Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer","volume":"53","author":"Thomas","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2009.04.015_bib35","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa030660","article-title":"The influence of finasteride on the development of prostate cancer","volume":"349","author":"Thompson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.juro.2009.04.015_bib36","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1056\/NEJMe038109","article-title":"The prevention of prostate cancer\u2013the dilemma continues","volume":"349","author":"Scardino","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.juro.2009.04.015_bib37","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1056\/NEJM200310163491615","article-title":"Prevention of prostate cancer with finasteride","volume":"349","author":"Roehrborn","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.juro.2009.04.015_bib38","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1056\/NEJMoa031918","article-title":"Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter","volume":"350","author":"Thompson","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.juro.2009.04.015_bib39","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/jnci\/djj307","article-title":"Effect of finasteride on the sensitivity of PSA for detecting prostate cancer","volume":"98","author":"Thompson","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.juro.2009.04.015_bib40","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1093\/aje\/kwh101","article-title":"Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker","volume":"159","author":"Pepe","year":"2004","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.juro.2009.04.015_bib41","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.juro.2007.01.071","article-title":"Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection","volume":"177","author":"Thompson","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2009.04.015_bib42","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.juro.2007.03.012","article-title":"Finasteride decreases the risk of prostatic intraepithelial neoplasia","volume":"178","author":"Thompson","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2009.04.015_bib43","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/jnci\/djm023","article-title":"Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial","volume":"99","author":"Moinpour","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.juro.2009.04.015_bib44","series-title":"Measuring Functioning and Well-Being: The Medical Outcomes Study Approach","first-page":"194","article-title":"Social functioning: sexual problems measures","author":"Sherbourne","year":"1992"},{"key":"10.1016\/j.juro.2009.04.015_bib45","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1093\/jnci\/djm117","article-title":"Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial","volume":"99","author":"Lucia","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.juro.2009.04.015_bib46","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1158\/1940-6207.CAPR-08-0092","article-title":"Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach","volume":"1","author":"Redman","year":"2008","journal-title":"Cancer Prev Res (Phila Pa)"},{"key":"10.1016\/j.juro.2009.04.015_bib47","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1158\/1940-6207.CAPR-07-0007","article-title":"Estimating rates of true high-grade disease in the Prostate Cancer Prevention Trial","volume":"1","author":"Pinsky","year":"2008","journal-title":"Cancer Prev Res (Phila Pa)"},{"key":"10.1016\/j.juro.2009.04.015_bib48","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1198\/016214508000000706","article-title":"Does finasteride affect the severity of prostate cancer?","volume":"103","author":"Shepherd","year":"2008","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.juro.2009.04.015_bib49","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1093\/jnci\/djm130","article-title":"Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial","volume":"99","author":"Cohen","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.juro.2009.04.015_bib50","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1158\/1940-6207.CAPR-08-0078","article-title":"Pathologic characteristics of cancers detected in the Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention","volume":"1","author":"Lucia","year":"2008","journal-title":"Cancer Prev Res (Phila Pa)"},{"key":"10.1016\/j.juro.2009.04.015_bib51","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.urology.2005.03.002","article-title":"Utility of saturation biopsy to predict insignificant cancer at radical prostatectomy","volume":"66","author":"Epstein","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.juro.2009.04.015_bib52","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1001\/jama.271.5.368","article-title":"Pathologic and clinical findings to predict tumor extent of nonpalpable (Stage T1c) prostate cancer","volume":"271","author":"Epstein","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.juro.2009.04.015_bib53","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/jnci\/djj131","article-title":"Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial","volume":"98","author":"Thompson","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.juro.2009.04.015_bib54","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.urology.2008.01.025","article-title":"Does the level of prostate cancer risk affect cancer prevention with finasteride?","volume":"71","author":"Thompson","year":"2008","journal-title":"Urology"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0022534709009008?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0022534709009008?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2009.04.015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T17:36:05Z","timestamp":1685036165000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2009.04.015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["10.1016\/j.juro.2009.04.015"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2009.04.015","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}